Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06264180
Title VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
Acronym IGNYTE-3
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Replimune Inc.
Indications
Therapies
Age Groups: child | senior | adult
Covered Countries USA


No variant requirements are available.